New technologies for pancreatic cancer treatment

Share This Post

Pancreatic cancer is a malignant tumor of the digestive tract that is highly malignant and difficult to diagnose and treat. It is hailed as the “king of cancer” by the medical profession. The 5-year survival rate is <1%, which is the worst prognosis of all malignant tumors. Cancer, its morbidity and mortality have increased significantly in recent years. The early diagnosis rate of pancreatic cancer is not high, the surgical mortality is high, and the cure rate is very low. Italian tenor singer Pavarotti, “fatty” Shen Dianxia and the father of Apple Jobs died of pancreatic cancer.

Global Oncologist Network reminds the majority of pancreatic cancer patients that, like most tumors, there has not been a treatment plan to completely cure pancreatic cancer. Patients should use surgical radiotherapy and chemotherapy as the main treatment methods, and cooperate with other new technologies for multidisciplinary treatment. Comprehensive Treatment.

Global Oncologist Network, as a platform that brings together global anti-cancer technologies and anti-cancer experts, can provide treatment technologies for pancreatic cancer patients, and can provide expert online consultation and remote consultation services for patients. Patients can log on the Global Oncology Doctor Network to learn more about the following new technology.

1. Speed ​​knife: It is the most advanced non-invasive tumor removal technology to date, and it is an upgraded version of the wave knife. It can treat benign or malignant solid tumors in any part, especially important organs or tumors near major blood vessels and nerves. It is excellent for solid tumors such as head tumors, lung cancer, spine tumors, liver cancer, pancreatic cancer, etc. Treatment effect. The 1-year and 2-year survival rates of patients with stage II pancreatic cancer treated by Sufeng knife were 76.9% and 46.7%, respectively, and the overall 1–5 year survival rates of patients with stage I and II pancreatic cancer were 67.7%, 34.4%, 29.6%, and 20.7, respectively. % And 17.3%, the median survival time is 17 months; the five-year survival rate is increased from 5% to 17%, while the risk is low, the pain is small, and the cost is low.

2. Nano-knife: Anti-cancer technology Nano-knife is derived from irreversible electroporation technology (IRE). Its principle is to use the powerful electric field emitted by high-voltage direct current to destroy the structure of the cell membrane and produce multiple pores in the cell membrane to make it irreversible. Destroys the cells, causing immediate cell death. Compared with surgery or other radio frequency, cryoablation, the advantage is that it will not cause irreversible damage to other important tissues in the ablation zone, such as blood vessels, bile ducts, nerves, etc .; and minimally invasive, less damage, less pain, and quick recovery . Data from the University of Louisville in the United States indicate that the combination of nanoknife and general treatment can double the overall survival rate of patients with locally advanced pancreatic cancer.

3. Proton knife: The physical properties of proton therapy allow energy to be stored at a specific depth, also known as the Bragg peak. After reaching a specific depth, the proton can achieve rapid attenuation of energy, resulting in little or no radiation dose absorbed by normal tissues To reduce treatment toxicity. At present, the Global Oncologist Network can assist domestic pancreatic cancer patients to go to the United States, Germany, Italy, Japan, Taiwan and other regions to receive proton therapy.

4. Electric field therapy: The anti-cancer technology “electric field therapy” approved by the US FDA affects the tumor cell division of the lesion through a low-intensity low-frequency electrostatic wave electric field, resulting in cancer cell apoptosis. The biggest feature of electric field treatment is that it does not damage the immune system, is relatively safe, has no side effects, does not harm normal cells, effectively removes cancer cells, prevents recurrence and metastasis, etc. It can be used in conjunction with surgery, radiotherapy, chemotherapy and other means to prevent pancreatic cancer recurrence. At present, electric field treatment is only carried out in the United States, Japan, and Israel, and patients can receive treatment through the Global Oncologist Network.

5. Gene targeted therapy: Targeted therapy through genetic testing is a milestone achievement in the treatment of pancreatic cancer. Targeted therapy, also known as “missile therapy”, has high selectivity and can strike cancer cells stably. Through genetic testing, oncologists can use targeted drugs to effectively treat pancreatic cancer and prolong the lives of patients. For example, the targeted drugs for pancreatic cancer mutant genes EGFR and mTOR mainly include erlotinib and everolimus. According to genetic testing experts from the Global Oncologist Network, the US pancreatic cancer gene testing technology is more comprehensive than domestic ones, with more and more accurate detection of genetic loci and targeted drugs.

6. Cellular immunotherapy: Cellular immunotherapy is a method of in vitro cultivation and expansion of healthy human immune cells into the patient’s body to stimulate and enhance the body’s own immune function, so as to achieve the purpose of treating tumors. Allogeneic umbilical cord blood stem cell immunotherapy is achieved by taking fetal umbilical cord blood immune cells and hematopoietic stem cells for cultivation, reintroducing them into the patient’s body, and killing cancer cells with immune cells from healthy people, which has achieved good therapeutic effects. Allogeneic cell immunotherapy can effectively cooperate with surgery, radiotherapy and chemotherapy to eliminate cancer cells and improve the five-year survival time.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Claudin18.2-targeted CAR-T cell therapy brings complete remission in advanced pancreatic cancer patient A case report
CAR T-Cell therapy

Claudin18.2-targeted CAR-T cell therapy brings complete remission in advanced pancreatic cancer patient : A case report

Claudin18.2-targeted CAR-T cell therapy has shown remarkable potential in treating advanced pancreatic cancer, as highlighted in a recent case report. This innovative approach led to complete remission in a patient with advanced disease, underscoring the promise of targeted immunotherapy. By leveraging the specific expression of Claudin18.2 on cancer cells, this therapy offers a precision-based treatment, heralding a new era in pancreatic cancer management with significant clinical implications.

What is the treatment after BCMA CAR T failed in RR multiple myeloma cases
CAR T-Cell therapy

What is the treatment after BCMA CAR T failed in R/R multiple myeloma cases?

For people with relapsed or refractory multiple myeloma, BCMA CAR T-cell therapy might not work. Other treatments, such as bispecific antibodies, other CAR T-cell therapies that target different antigens, and combination regimens with immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies, can still be used. OriCAR-017 is another immunotherapy that is under trial and is expected to be launched soon. Clinical trials offer experimental treatments, providing access to novel therapies. Tailored approaches based on patient-specific factors and emerging research are crucial for improving outcomes in this challenging scenario.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy